Skip to main content
Fig. 2 | Respiratory Research

Fig. 2

From: Tocilizumab improves 28-day survival in hospitalized patients with severe COVID-19: an open label, prospective study

Fig. 2

Allocation to usual care was associated with significant increase in 28-day mortality compared to tocilizumab plus usual care [Cox proportional-hazards model: HR: 3.34, (95% CI: 1.21–9.30), (p = 0.02)], (A). There was not a statistically significant difference with regards to hospital discharge over the 28-day period for patients receiving tocilizumab compared to usual care [11.0 days (95% CI: 9.0–16.0) vs 14.0 days (95% CI: 10.0–24.0), HR: 1.32 (95% CI: 0.84–2.08), p = 0.21], (B)

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us